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Pathophysiological mechanisms of vascular calcification in end- of cardiovascular mortality, it remains to be shown con-
stage renal disease. Vascular calcification has been clearly de- clusively that this is caused by accelerated atherosclerosis
fined as a risk factor for cardiovascular mortality in the general per se, and other factors have been implicated [9, 10].population and is highly prevalent in end-stage renal disease
One such factor may be vascular calcification (VC). VC(ESRD), where it is associated with a number of markers of
is clearly important in the general population, where coro-increased mortality such as left ventricular hypertrophy. The
pattern of calcification in ESRD is characterized by mineral nary artery calcification correlates with and predicts mor-
deposition in the tunica media, in contrast to non-ESRD popula- tality [11]. In CRF, histologic [6] and radiographic [12]
tions, where calcification of atheromatous plaque predomi- evidence of VC is much more striking than in the generalnates. This difference may have important clinical implications.
population, and it has been shown to have an importantThe pathophysiological mechanisms underlying both types of
adverse influence on a number of surrogate markersvascular calcification remain to be clarified; however, current
evidence suggests that they are active processes rather than for CVD mortality such as left ventricular hypertrophy
passive mineral precipitation, and the presence in the vascula- (LVH) [13]. Several explanations for this marked calci-
ture of cells expressing an osteoblastic phenotype may be of fication in CRF are proposed, including the presence of
central importance. In ESRD, the presence of secondary and
dysregulation of calcium/phosphate metabolism implicittertiary hyperparathyroidism, disordered calcium and phos-
in renal osteodystrophy (ROD), as well as the iatrogenicphate homeostasis, and the use of vitamin D- and calcium-
based treatments in its therapy may all contribute to vascular influence of its treatment with calcium-containing phos-
calcification. These issues and the impact on other current and phate binders and with vitamin D analogues. In addition,
future therapies have great importance for clinical nephrology, new therapies emerging for the treatment of various
and a better understanding of vascular calcification through a
aspects of CRF, such as bone morphogenetic protein 7focused research effort is essential.
(BMP-7) for renal fibrosis [14], may theoretically exacer-
bate VC [15] and may, in turn, have a significant negative
impact on mortality. At present, understanding of theRegistry data from both the United States and North-
processes and implications of VC is incomplete, andern Europe have consistently demonstrated an excess
there are few data that specifically relate to VC in themortality in patients with end-stage renal disease (ESRD)
context of CRF. Here, we present an interpretation of[1, 2], despite measures to optimize dialysis treatment.
the current state of understanding of VC from the view-Approximately 50% of all deaths are attributed to car-
point of CRF, speculate on putative pathophysiologicaldiovascular disease (CVD) [3], and this remains one of
mechanisms, and discuss its impact on current and futurethe major outstanding issues in clinical nephrology. An
management of CRF.influential article by Lindner et al concluded that acceler-
ated atherosclerosis was the major cause of this excess
cardiovascular mortality [4]. Given the high incidence ARTERIOPATHY IN CHRONIC
of established cardiovascular risk factors in the chronic RENAL FAILURE
renal failure (CRF) population, this is an attractive hy- Vascular calcification has been recognized for over
pothesis; however, subsequent reports have challenged 150 years [16]. For most of that time, it has been regarded
its validity [5–8]. While there is undoubtedly an excess as a passive process associated with atherosclerosis or
normal aging, resulting from the accumulation of debris
from cell necrosis. It has not been thought to be clinicallyKey words: medial vascular calcification, osteoblast-like cell, renal os-
important and, as a result, received little scientific atten-teodystrophy, hyperparathyroidism, left ventricular hypertrophy, min-
eral deposition, atheromatous plaque. tion. However, in the last decade, evidence has emerged
to suggest that VC is an active and regulated process 2001 by the International Society of Nephrology
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with important clinical consequences [11, 13, 15] and that J Am Soc Nephrol 11:280A, 2000). LVH is an indepen-
dent risk factor for cardiac mortality in the ESRD popu-it may be particularly important in CRF. Two patterns
of calcification are recognized. First, in the context of lation, and while undoubtedly multifactorial in origin in
this patient group (influenced among other factors byatherosclerotic plaque formation, calcification occurs in
association with lipid-laden foam cells at the base of the chronic anemia, hypertension, fluid overload, iron over-
load, and the direct effects of parathyroid hormone onplaque in proportion to the severity of the lesion [17].
This process is focal, and adjacent regions of the vessel cardiac fibrosis), the striking VC that is often present is
likely to play an important role in its etiology. Recentwall may be remarkably normal. The second form of
calcification is sometimes referred to as Mo¨nckeberg’s data have clearly demonstrated that VC is correlated to
increased stiffness of large arteries and LVH in the renalsclerosis and is characterized by diffuse mineral deposi-
tion throughout the vascular tree [18], occurring predom- population [13] independent of age and hypertension.
In addition to these considerations, a form of VC thatinantly in the media of the vessel, particularly at the
internal elastic lamina, and with no relationship to ather- may be specific to renal failure has been described [26–28].
Calciphylaxis, or uremic arteriolopathy, manifests as a pain-omatous plaque formation. This form of calcification is
characteristic of aging, but is also a striking feature of ful necrotizing rash that spreads rapidly from the periph-
ery to the trunk and is associated with a high mortality.the vascular disease seen in diabetes mellitus (DM) [18]
and CRF [6, 19]. It is important to note that the vast Histologically, it is characterized by medial calcification
of cutaneous and subcutaneous arteries and arterioles,majority of patients with VC, whether related to athero-
sclerosis or not, have normal calcium and phosphate with associated occlusive intimal proliferation. Little is
known about its etiology, but it has been associated withmetabolism.
Vascular calcification is common in CRF, often from poorly controlled ROD and a longer duration of ESRD
[28], although the importance of hyperparathyroidism hasa young age [12]. Medial calcification may be particularly
striking compared with other clinical situations and cor- been questioned [29]. Whether calciphylaxis is a separate
relates to duration of hypertension and duration of renal process to medial VC of large vessels or simply a more se-
disease [6]. It is also often associated with intimal prolif- vere form of the same process in which the intimal fibrosis
eration [19], which in turn correlates with hyperparathy- is sufficient to occlude critically small vessels is not clear.
roidism and hyperphosphatemia [20], both common in
ESRD. It primarily affects the aorta, but plain x-rays
PATHOGENESIS OF VASCULARoften show a characteristic tramline appearance of calci-
CALCIFICATION: A CENTRAL ROLEfication extending to the peripheral small vessels, a find-
FOR AN OSTEOBLAST-LIKE CELL?ing confirmed histologically [19].
A number of lines of evidence suggest that VC is anThe clinical significance of these changes derives from
active process [30]. First, clinical and histological descrip-biophysical alterations in the vasculature. Calcification
tions have noted structures resembling bone and evenaround atherosclerotic lesions increases plaque fragility,
bone marrow in calcified vessels [31]. Second, the partic-which in turn makes that part of the vessel wall more
ular form of calcium phosphate crystal found in vesselvulnerable to shear stresses, precipitating acute plaque
walls is hydroxyapatite, the form found in bone [15].rupture and thrombosis [17]. This is likely to explain
Third, matrix vesicles, which are the focus of initiation forthe correlation between coronary artery calcification and
calcification in normal mineralizing endochondral bone,mortality [11], and complications after angioplasty [21]
have been described in calcifying vessel walls [32, 33].and bypass surgery [22]. The confluent nature of the
Fourth, immunohistochemistry and in situ hybridizationmineralization of medial calcification influences morbid-
have demonstrated a variety of characteristic bone-relatedity and mortality differently, primarily by stiffening the
proteins in association with calcified atheromatous plaque,vessel wall and reducing vascular compliance [23]. The
including collagen I [34], the major collagen of bonehemodynamic consequences of this include an increase
extracellular matrix (ECM), and a number of noncollag-in systolic blood pressure in association with a fall in
enous bone matrix proteins, including BMP-2a [15], os-diastolic pressure, giving a widened pulse pressure, in-
teopontin (OPN) [35–39], osteocalcin [30], matrix GLA-creased pulse-wave velocity, and increased left ventricu-
protein (MGP) [37], and alkaline phosphatase [reviewedlar afterload. In turn, these changes have been shown to
in 30, 31, 40]. While the presence of these proteins couldlead to both LVH and altered coronary perfusion [13].
be interpreted as a response to calcification rather thanHuman studies [13, 23] and animal models [24, 25] have
its driving mechanism, the presence of osteocalcin, whichdemonstrated the association between these vascular and
is regarded as pathognomonic of osteoblastic terminalcardiac changes in CRF, and recently reported data from
differentiation, suggests a role for a cell expressing anthe U.S. Renal Data System specifically confirm that
osteoblastic phenotype as a central component in itspulse pressure is widened in the CRF population com-
pared with the general population (abstract; Klassen, etiology, a hypothesis supported by in vitro data.
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Table 1. Factors influencing calcification of vascular smooth muscle to the etiology of VC, it nevertheless remains to be
cells and pericytes in vitro confirmed by in vivo observation, and this hypothesis
raises a number of questions. First, what might be theFactors increasing calcification Factors decreasing calcification
origin of these cells? Second, what is their primary role,cAMP [46] Autocrine/paracrine PTHrP [55]
Inorganic phosphate [41, 49] Osteopontin [42] assuming the calcification process to be pathological?
Alkaline phosphatase [41] Collagen IV [45] Third, how is calcification stimulated? Fourth, what
Corticosteroids [50]
mechanisms lead to their appearance?Vitamin D3 [51]
Estrogens [52]
Oxidized lipids [48] Origin of the osteoblast-like cell
TGF-1 [48]
It has been suggested that the properties of CVCs areAdvanced glycation
end products [53] in vitro phenomena; nevertheless, the cells are derived
Collagen I [45] ex vivo, and clearly not all cells derived from medial
? ‘Intracrine’ PTHrP [54]
vascular explants behave similarly in culture, as noted
Abbreviations are: cAMP, cyclic adenosine monophosphate; TGF-1, trans- previously in this article. The fact that at least two popu-forming growth factor-1; PTHrP, parathyroid hormone-related peptide.
lations of cells are encountered, one calcifying and one
not, strongly suggests the presence of at least two popula-
tions in the original tissue. The origin of these CVCs is
Demer et al [15], and subsequently others [41, 42], have not clear, however, and remains a matter of debate. It
derived primary vascular smooth muscle cell (VSMC) cul- has been hypothesized that that CVCs may be derived
tures from explants of medial tissue of both normal and from microvascular pericytes in view of a number of
diseased vessels, which adopt a calcifying phenotype in common characteristics, including morphology on light
vitro and express the wide array of bone-related proteins and electron microscopy, expression of cell surface and
mentioned previously in this article [15]. Of particular sig- secreted proteins [56], and the ability to calcify [49].
nificance is the observation that these calcifying VSMCs, Pericytes, smooth muscle cells, and osteoblasts are all
termed calcifying vascular cells or CVCs, follow the criti- derived from common marrow mesenchymal stem cells.
cal sequence and timing of expression of these proteins While mature osteoblasts have reached an irreversible
as it occurs in normal mineralizing bone [43, 44]. As cells state of end differentiation and are unable to re-enter
differentiate to mature osteoblasts in bone, the ability the cell cycle, pericytes, and to a lesser extent smooth
to proliferate is lost, while at the same time synthesis of muscle cells, retain their pluripotentiality and have the
appropriate matrix components begins, predominantly capability to become osteoblasts [40, 57]. However, con-
collagen I. In turn, accumulating matrix signals to the cell clusive proof of this derivation is lacking, in part because
to initiate secretion of proteins relating to mineralization, no specific marker for pericytes has yet been described.
first alkaline phosphatase and OPN, later osteocalcin It is also unclear whether these cells with osteoblastic
and MGP. The synthesis of an appropriate type of matrix potential are normally resident in the vessel wall (the
critically influences calcification [45]. Collagen I and fi- fact that CVCs are derived from the media of normal
bronectin enhance the process, while collagen IV inhibits vessels suggests this is so [15]); whether they derive from
it. These influences appear to be mediated through integ- pericytes migrating from, for example, the adventitial
rins involved in cell/matrix interaction [45]. In addition, microvasculature; or whether from marrow stromal cells
CVCs express the transcription factor cbfa1/osf2 [46], a reaching the vessel wall via the circulation [58]. In addi-
factor both essential and sufficient for differentiation of tion, in a review of their own and other work on pericytes,
the mature osteoblast in bone [47]. However, whether Doherty and Canfield state that pericytes express cbfa1/
the ability to calcify is a characteristic of all VSMCs is osf2 [59]. If this were indeed the case, then pericytes
not clear. CVC clones calcify spontaneously and rapidly would clearly be cells capable of expressing an osteoblas-
throughout their existence in vitro; in contrast, other tic phenotype; however, as yet there are no published
VSMCs clones derived from the same explants never do data to support this claim.
so [48]. This difference may depend on the ability of
Role of the osteoblast-like cellindividual clones to synthesize an appropriate matrix
[45]. A number of studies have investigated the process If an osteoblast-like cell is indeed central to VC, this
of calcification in this cell line, suggesting that it is a is unlikely to be its prime purpose in the vasculature,
cAMP-mediated mechanism [46] and influenced by a since VC is clearly pathological, as evidenced by the
variety of factors (Table 1) [41, 42, 45, 46, 48–55]. Chronic epidemiological data given previously in this article.
stimulation of CVCs with cAMP causes a confluent calci- More likely is that its differentiation fulfills a different
fication throughout the cell monolayer that is strikingly role, but that calcification is initiated as an undesired
similar to in vivo medial calcification seen in CRF secondary process. We hypothesize that this prime role
may be related to vascular repair. Vessel wall repair[46].However, if an osteoblast-like cell is indeed central
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involves migration and proliferation of certain cell types, in favor of mineralization would lead to significant calci-
fication over time, and whereas an acute vascular injuryparticularly smooth muscle cells. In order to migrate, a
cell must release itself from its ECM attachments. One such as that seen after angioplasty would lead to a short-
term response, a state of chronic vascular injury such asimportant role of the ECM attachment is to provide a
survival signal, and a migrating cell needs to overcome that seen in CVD would lead to an environment condu-
cive to calcification over a protracted period.its lack of fixation to the ECM to avoid apoptosis. OPN
has been demonstrated to act as an anti-apoptotic signal Indeed, by analogy with the function of osteoblasts in
normal bone, the very presence of osteoblast-like cells infor osteoclasts in their normal function [60] and for mi-
grating vascular endothelial cells responding to vessel the vasculature could lead to a procalcific environment.
Bone mass varies in response to applied strain; athleticwall injury, functions mediated through up-regulation of
osteoprotegerin expression via an v3/nuclear factor-B– exercise, for example, is a stimulus for increased bone
mass, and in contrast, bed-bound patients and astronautsdependent pathway [61]. In the clinical setting, OPN is
highly up-regulated during neointima formation during in the weightless environment of space rapidly lose bone
mass. Although the mechanism of this response is notVSMC proliferation and migration following angioplasty
[62], suggesting that it may play a similar role in this cell well understood, one early component of it is an increase
in intracellular calcium concentration mediated by stretch-type. A further function of OPN that may be relevant
is that it can also act as a chemotactic factor for macro- activated cation channels (SA-CAT) [66], which leads
to changes in cytoskeletal architecture [67], up-regula-phages and monocytes in models of renal disease, and
this role is supported by observations in specific human tion of expression of markers of bone anabolism such
as OPN [68], and increased mineralization in vitro [69].renal diseases [63]. Macrophages have a clearly defined
role in the etiology of atheroma, and OPN may contrib- SA-CAT has also been described in VSMCs [70]. Thus,
one can hypothesize that an osteoblast-like cell in theute to their recruitment in this context. Therefore, if
OPN were an appropriate survival or chemotactic factor vessel wall would respond to relatively high levels of
repetitive strain in relationship to the cardiac cycle in ain the context of vascular injury, then the differentiation
of an osteoblast-like cell would serve as an efficient similar manner, particularly in proximal large vessels,
leading to up-regulation of mineralization. In addition, inmechanism for its production.
CRF, hypertension, fluid overload, and an up-regulated
Mechanism of calcification renin-angiotensin system (RAS) all increase vessel wall
strain, even in distal parts of the circulation less affectedThe role of these putative osteoblast-like cells in the
mineralization process is also a matter of debate. The by the cardiac cycle per se. Animal studies suggest that
an increase in vessel wall strain may be an early event,ability to secrete an appropriate matrix for mineraliza-
tion as well as alkaline phosphatase, which is essential for preceding structural changes in the vasculature in a
model of uremia in rats [71]. However, this explanationmineralization to begin, and other bone-related proteins
suggests that they could promote VC, but this is coun- remains speculative.
tered by observations from knockout mice. First, mice
Recruitment of the osteoblast-like cellwith a deletion of MGP develop dramatic VC shortly
after birth and die in the neonatal period from aortic What causes the osteoblastic cell to occur in the vascu-
lature? The confluent and extensive nature of medialrupture [64]. Second, OPN knockout mice develop an
enlarged and stronger skeleton characterized by larger VC in CRF suggests that whatever initiates this process
affects the vascular tree widely and relatively evenly. Wehydroxyapatite crystals (abstract; Kizer et al, Am Soc
Bone Miner Res 15:S343, 2000). A similar skeletal pattern hypothesize that chronic vascular injury, by factors such
as hypertension, chronic fluid overload, and systemic up-is associated with a milder form of VC in osteoprotegerin
knockout mice, a protein moderating osteoclastic activity regulation of the RAS, is important to this process. All
are common in CRF and affect the vascular tree evenly,that is, in turn, modulated by OPN [65]. These data
suggest that OPN and MGP act primarily to restrain provoking changes in the vascular wall such as smooth
muscle proliferation, medial hyperplasia, and increasedmineralization and, therefore, that VC may occur as a
result of failure of these mechanisms. It is likely that vessel wall stress.
One factor that may be crucial to the vascular responseosteocalcin, like MGP a -carboxylated GLA protein,
has a similar function. The explanation for this apparent to chronic injury and that may influence the calcification
process is parathyroid hormone-related peptide (PTHrP).paradox is likely to be that in the vasculature, as in bone,
cells expressing the osteoblastic phenotype both initiate PTHrP was first described as the agent of hypercalcemia
of malignancy and has a high degree of sequence homol-and subsequently regulate calcification, and that the re-
sulting amount of mineralization reflects a fine balance ogy to PTH at the amino terminus as well as sharing
equal affinity for their common receptor, PTH1R [re-between these opposing influences. In the absence of
osteoclastic activity in the vasculature, a small imbalance viewed in 72–74]. However, this region accounts for only
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about one third of PTHrP, and the remainder of the autocrine, paracrine or intracrine functions predominate
in vivo is not known, and as discussed later in this article,protein is divergent from PTH. Several peptides may be
derived from both the midregion and carboxy terminal, other components of the uremic milieu are likely to in-
fluence its behavior.and although their precise physiological roles remain
unclear, they appear to be involved in calcium metabo-
lism [73, 74]. Expression of PTHrP is widespread in vas-
INFLUENCE OF CRF AND ITS
cular tissue, where it acts in an autocrine or paracrine
TREATMENT ON VC
fashion and, importantly, is up-regulated by vessel wall
A number of issues relatively specific to CRF maystress and vasoconstricting agents such as angiotensin II
influence the processes described previously in this arti-[73]. Thus, the situation in CRF of hypertension, fluid
cle, which may in turn account for the striking medialoverload, and overactivity of the RAS is likely to up-
VC seen. First, hyperparathyroidism is very commonregulate it throughout the vascular tree. Expression is
in CRF, and PTH has been demonstrated to increasealso up-regulated during acute experimental vascular in-
intracellular calcium; as noted previously, this is a stimu-jury [75] in a time-dependent fashion, in parallel with
lus for calcification in the osteoblast. PTH is likely tovessel wall repair and VSMC migration and proliferation.
interact with PTHrP function since PTH acts to down-The finding of PTHrP in atherosclerotic plaque confirms
regulate the common PTH1R receptor. This would im-its relevance to clinical disease [75]. The effects of PTHrP
pair the antimineralizing influence of PTHrP and mayon VSMCs and CVCs are complex [72]. PTHrP has been
cause it to act preferentially through other pathways thatshown to inhibit VSMC proliferation when acting through
encourage calcification. In addition, the function of manyPTH1R [72, 76, 77], but has the opposite effect when its
subpeptides of PTHrP and the receptors through whichgene is experimentally overexpressed within the cells
they act is not known. These peptides may be relevant[54, 72]. This “intracrine” effect is mediated by its ability
since the carboxy-terminal fragments accumulate into escape the secretory mechanisms of the cell and trans-
CRF. Other receptors, for which PTH and PTHrP havelocate to the nucleus [74], where it is able to act as a
differential affinity, have been described and hypothe-transcription factor, leading to VSMC proliferation, and
sized [74, 79] but need further characterization. In addi-thus contributing to vessel wall hypertrophy. The fact
tion, PTH has also been linked with intimal proliferation,that PTHrP up-regulation is followed rapidly by down-
which may be significant in the etiology of calciphylaxis.regulation of PTH1R suggests that this latter function
Second, a high calcium/phosphate (CaxPO4) productmay be more pathophysiologically relevant. When ap-
has consistently been associated with increased VC [3, 12].plied exogenously to CVCs, PTHrP reduces calcification
Patients with CRF often fail to achieve their target phos-[55] and is able to antagonize the calcifying influence of
phate level, and a high CaxPO4 product is maintainedvitamin D3 [51]. However, the effects of overexpression
in part by the widespread use of calcium carbonate as aof endogenous PTHrP are not known in this context. A
phosphate binder, which in the context of concurrentfurther paradox is the fact that exogenous PTHrP acting
use of vitamin D analogues often leads to a mild hyper-through PTH1R would be expected to increase cAMP,
calcemia. The prescribed dose of calcium carbonate hasone of the secondary messengers of this receptor; how-
been correlated to degree of VC as well as vascularever, cAMP has been shown to increase calcification
stiffness and LVH in a recent clinical study [13].in CVCs (discussed previously in this article), whereas
Third, vitamin D analogues, also widely prescribed forPTHrP has the opposite effect.
ROD, may have adverse effects, but the issue needsIn addition, PTHrP is clearly involved in bone physiol-
clarification. Vitamin D has long been known to causeogy [73]. It is known to be involved in normal skeletal
VC in humans and other species [80], characteristicallydevelopment, controlling chondrocyte proliferation and
in the media of the vessel wall. VSMCs express vitaminmaturation, and orchestrating generation of an appro-
D receptors, and vitamin D inhibits proliferation of thesepriate ECM for subsequent calcification. PTHrP has also
cells by acute influx of calcium into the cell; however,been shown to increase proliferation of an osteoblast cell
in a cell expressing an osteoblast-like phenotype, thisline in vitro, but appears to restrain differentiation [78].
may be a stimulus to initiate mineralization [66]. It hasThe same study showed that PTHrP expression was asso-
been shown that vitamin D3 increases expression of alka-ciated with down-regulation of BMP-2 and alkaline phos-
line phosphatase in VSMCs in culture [51] and to in-phatase, changes likely to inhibit mineralization [78].
crease calcification by CVCs in vitro [25, 51]. On theTaken together, these data suggest that PTHrP has
other hand, vitamin D3 levels have been inversely corre-the potential to respond to the chronic vascular injury
lated with coronary calcification [81, 82], and vitamincharacteristic of CRF by promoting VSMC proliferation.
D3 has been shown to up-regulate MGP expression inIn addition, it can prepare the way for calcification by
cultured osteoblasts [83, 84] and rat VSMCS [85]. In addi-promoting osteoblastic proliferation and directing syn-
thesis of an appropriate matrix; however, which of its tion, vitamin D3 is able to down-regulate collagen I [86].
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These factors would tend to restrain calcification. These with CRF are deficient in this protein. ROD is character-
paradoxical influences are likely to depend on cell type, ized by a failure of full osteoblast differentiation and
differentiation state, and species, as well as the balance maturation, which may reflect BMP-7 deficiency; BMP-7
of particular vitamin D moieties present, and require clari- therefore may be a potential treatment for this condition.
fication. In addition, BMP-7 has been shown to ameliorate tubu-
Fourth, in vitro data have linked the presence of ad- lointerstitial fibrosis and preserve glomerular filtration
vanced glycation end products (AGEs) to VC [53]. While rate in rat models of both obstructive uropathy and dia-
this has obvious implications for diabetic patients with betic nephropathy, to a greater extent than angiotensin-
poor glycemic control, it has recently been shown that even converting enzyme inhibitors [14]. However, one of its
nondiabetic CRF patients have increased levels of AGE target genes is cbfa1/osf2, and if this factor is important
formation, attributable to carbonyl stress [87], and this may, in the etiology of VC, as noted previously in this article,
therefore, have wider implications for VC in CRF. then BMP-7 may have an adverse effect on cardiovascu-
Fifth, warfarin is commonly prescribed in ESRD and lar morbidity and mortality that may outweigh its bene-
also theoretically may promote calcification since MGP fits. Clearly, this issue needs clarification before BMP-7
and osteocalcin are both -glycosylated, warfarin-sensi- can be considered for clinical trials.
tive inhibitors of mineralization [85]. Rodent studies
have demonstrated that the enzyme system for regener-
ating oxidized vitamin K in the vascular wall is much CONCLUSION
less efficient than the hepatic system, and thus is far
In conclusion, VC is a widespread phenomenon thatmore sensitive to the effects of warfarin [88]. By analogy
has important consequences for long-term cardiovascu-with other enzyme systems, this system may be further
lar outcome. The mechanisms of its etiology are poorlyimpaired in uremia, which may lead to a procalcifying
understood, but are likely to reflect a balance betweenenvironment in the vasculature even at relatively low
a number of processes relating to vascular repair in re-levels of anticoagulation. It is interesting to note the
sponse to chronic injury. In addition, VC is likely toanecdotal association between warfarin and calciphylaxis
have a significant iatrogenic component in many patients.[89]. Nevertheless, it is difficult to draw emphatic conclu-
There are currently virtually no data concerning VC insions from rodent data since there are clear and impor-
CRF where strong circumstantial evidence suggests ittant interspecies differences relating to MGP. Whereas
MGP knockout mice have florid VC leading to prema- has an extremely important impact. ROD and its treat-
ture death [64], as noted previously in this article, pa- ment, the use of warfarin, and possibly other poorly
tients with the human equivalent of this situation, Keu- defined elements of the uremic milieu may contribute
tel’s syndrome, have no evidence of VC despite ectopic to its etiology in this setting. Better understanding of the
calcification at other cartilaginous sites [90]. processes underpinning VC may have important conse-
quences for the management of patients with CRF and
ESRF, both currently and in the future, as any therapyFUTURE DIRECTIONS
to retard or improve VC would be likely to have an
These considerations suggest that VC in CRF at least
important impact on mortality in this patient group, asin part may be an iatrogenic phenomenon, relating to
well as in a wider context.the use of calcium-containing phosphate binders, vitamin
Perhaps the most significant problem with the state ofD analogues, and anticoagulation. The introduction into
knowledge at present is the dearth of human data: Theclinical practice of alternative phosphate binders that do
majority of the work referred to here is from rodent ornot contain calcium [91], newer vitamin D analogues that
bovine models, mostly in vitro, and the example of MGPare less calcemic [92], and calcimimetic compounds for
suggests that there may be important interspecies differ-the control of hyperparathyroidism [93] may ameliorate
ences in the processes described. We advocate a focusedthis problem. The optimal control of fluid balance and
research effort in this area.hypertension also may contribute to an improvement.
In addition, recent work in our laboratory has sug-
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